At Novartis, we are as passionate about our patients as we are about our research. We are dedicated to our commitment to the communities and families affected by the conditions we are studying. We know that life with a rare disease can bring significant challenges to patients, their families, healthcare professionals, and we want to be as supportive as possible.
Whilst participating with 2 events in the ISSAID Periodic congress, we are honored to be an active ally in the communities we serve.
Wednesday 7 July 2021 – 18:00 - 19:00
Novel Approaches to Personalized Patient Care in Still’s Disease
Carine Wouters, Lorenzo Dagna, Johannes Knitza
Wednesday 21 July 2021 – 18:30 - 19:00
Meet the Expert: Still’s Disease and its Mimics
Eugen Feist, Sinisa Savic
In addition, event recordings will be available on-demand on the ISSAID platform until 31 December 2021.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.
The International Society of Systemic Auto-Inflammatory Diseases (ISSAID) raise awareness, catalyse basic research and promote scientific and clinical knowledge on all aspects of systemic auto-inflammatory diseases.
ISSAID 2021 c/o MCI Geneva
9, rue du Pré-Bouvier
1242, Satigny, Geneva
+41 22 33 99 673